Abstract: Alpha-1-antitrypsin deficiency (AATD) is associated with variable development of emphysema and other features of chronic obstructive pulmonary disease (COPD). Matrix metalloproteinases (MMPs) are believed to be important in the pathophysiology of COPD, and may therefore confer susceptibility to this phenotype in patients with AATD. Objectives: to assess the role of polymorphism of MMP1, MMP3 and MMP12 in AATD phenotypes. Methods: 424 PiZZ subjects from the UK AATD Registry were assessed for history of chronic bronchitis (CB), post-bronchodilator lung function impairment and decline of lung function. Tag single nucleotide polymorphisms (SNPs) for MMP1, MMP3 and MMP12 were chosen using HapMap (r 2 40.8, MAF40.05) and were genotyped using TaqMan Õ genotyping technologies. Quantitative genetic association was assessed using regression modelling to correct for covariates. Results: in patients with AATD, carriers of the G allele of rs678815 (MMP3) had lower gas transfer (KCO) (P ¼ 0.025, B ¼ À7.766) than the homozygous wild type, while carriers of the T allele of rs470358 (MMP1) had higher KCO (P ¼ 0.025, B ¼ 6.130). Conclusions: variations in MMP1 and MMP3 are associated with gas transfer in AATD, supporting a previous family study showing linkage of KCO to this gene region. Replication of these preliminary data is now required particularly if MMP inhibitors are to be considered as a therapeutic option.
Introduction
Chronic obstructive pulmonary disease (COPD), defined by progressive airflow limitation that is not fully reversible, is a heterogeneous condition with genetic and environmental risk factors, the most important of which is cigarette smoking [ATS, 1996] . However, the observation that only 15% of smokers develop clinically significant COPD [ATS, 1996] and that the rate of decline in lung function among smokers is variable [Fletcher and Peto, 1977] suggests that a geneenvironment interaction exists influencing disease expression.
Genetic susceptibility to COPD as a result of protease-antiprotease imbalance is the mechanism of disease in alpha-1-antitrypsin deficiency (AATD) [Stockley and Luisetti, 1999] .
Protease-anti-protease imbalance leads to increased destruction of elastin and extracellular matrix, resulting in subsequent parenchymal damage [Stockley, 1999] . The cross-links of elastin fibres, known as desmosines, are unique to elastin and may be used as a marker of its degradation [Harel, 1980] . Desmosine and elastin peptides are elevated in the plasma, urine and sputum of COPD patients [Ma et al. 2007] , while urinary levels positively correlate with the annual rate of decline in FEV1 in smokers [Gottlieb, 1996] , confirming the importance of connective tissue destruction in disease pathogenesis.
The gene for AAT is highly pleomorphic with over 100 single nucleotide polymorphisms (SNPs) catalogued on public databases [DeMeo and Silverman, 2004] . The most common deficiency allele in Northern Europe is the PiZ allele, which is associated with significant lung and liver disease [Needham and Stockley, 2004] . However, even within PiZZ subjects there remains considerable disparity in clinical phenotype and evidence is growing for the role of genetic modifiers within this group [DeMeo et al. 2008; Wood et al. 2007a Wood et al. , 2007b .
Matrix metalloproteinases (MMPs) compromise a structurally and functionally related group of 20 proteolytic enzymes, which play a key role in the tissue remodelling and repair associated with inflammation [Nagase and Woessner, 1999] . MMPs have been mapped to chromosomes 11, 14, 16, 20 and 22 with several being clustered on the long arm of chromosome 11 [Pendas, 1996] . Genetic association studies in the National Emphysema Treatment Trial (NETT) and Lung Health Study have implicated polymorphisms in MMP1 and MMP12 in COPD phenotypes [DeMeo et al. 2007; Joos et al. 2002] , both of which map to the chromosome 11 cluster. A family-based AATD study has also suggested a linkage between lung function and the chromosome 11 region [Stolk, 2007] .
Genetic association implies a role for the protein product in pathogenesis and thus a potential therapeutic target. Antioxidant, protease and inflammatory response genes all exhibit association with COPD, but often to different sub-phenotypes [Wood and Stockley, 2006] . Trials of antioxidant [Decramer et al. 2005] and anti-TNF [Rennard et al. 2007 ] therapies have been disappointing thus far, but the response may vary between patients according to their sub-phenotype [Rennard et al. 2007] , and could be dictated by genotype [Seitz et al. 2007] . Clear gene-phenotype associations are important to identify with regard to selection of patients for future drug trials, in order to maximise their power. We have performed a candidate gene association study on the MMP cluster in a highly characterised group of British AATD subjects, seeking to replicate the regional association seen [Stolk, 2007] and further categorise the phenotype in whom this group of genes may play a role.
Methods

Clinical phenotyping
Four-hundred-and-twenty-four unrelated Caucasian subjects from the UK national registry for AATD were studied. Approval was given by the local ethics committee and all gave informed consent. All patients had a serum alpha-1-antitrypsin (AAT) level of 511 mM, PiZZ genotype confirmed by specific PCR (Heredilab, Salt Lake City, UT, USA) and had never received AAT replacement. A full clinical assessment including smoking history, lung function testing and high resolution CT scanning of the chest was performed as described previously [Dowson et al. 2001] . Annual measurement of lung function allowed assessment of rate of decline of FEV1 in a subset of subjects with at least 3 years follow up.
The presence, distribution and severity of emphysema was determined by the visual appearance of the scan and density mask analysis of slices at the level of the aortic arch, representing the upper zone, and at the inferior pulmonary vein, representing the lower zone, using a threshold of 910 HU. This is the most commonly used threshold level for emphysema detection, deemed optimum by Muller et al. [1988] and validated against physiological measures in AATD . Patients whose voxel index exceeded values seen in normal subjects in either zone [Soejima et al. 2000] were classified as having emphysema.
Genotyping
The three candidate genes closest to the peak LOD score within the MMP cluster on chromosome 11 [Stolk, 2007] were identified as MMP1, MMP3 and MMP12. SNPs to tag these genes were chosen using HapMap [International HapMap Consortium, 2005 ] data for Caucasian subjects, according to established methods [Newby et al. 2007] . Using a cut off of r 2 40.8, 16 tags were identified to capture all SNPs with minor allele frequency40.05. A total of 40 SNPs were captured: 13 in MMP1, 14 in MMP3, and 13 in MMP12. DNA extraction was performed using a modified Nucleon Bacc II kit (Tepnel Life Sciences, UK) and quantified using Picogreen Õ (Molecular Probes Inc., UK). Genotyping was carried out using TaqMan Õ genotyping technologies (Applied Biosystems, UK) on an ABI7900 HT. All genotyping assays were prevalidated by the suppliers, and all plates included appropriate negative controls. One tag SNP (MMP12 rs476185) failed design due to a high GC content in the region.
Statistical analysis
Deviation from Hardy Weinberg equilibrium was checked for all SNPs, and additive models assumed.
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Data was analysed using SPSS (version 12, November 2003, Chicago: SPSS Inc.) and haplotype analyses carried out in Haploview [Barrett et al. 2005 ]. The haplotype identified was then analysed for association within SPSS. Comparisons of demographic and clinical features between subgroups were carried out using the Mann Whitney or t-tests, as appropriate. Linear regression was used to calculate postbronchodilator FEV1 decline, such that the slope of the line between time zero and 3 years for each patient represented loss per year.
Being a quantitative genetic association study, linear regression was used to assess association of each tag with FEV1, KCO, severity of upper and lower zone emphysema (indicated by the upper zone voxel index (UZVI) and lower zone voxel index (LZVI) respectively) and FEV1 decline. All regression models were corrected for age, gender and smoke exposure.
Results
Clinical phenotypes
The clinical features of the subjects are shown in Table 1 . Three-hundred-and-forty-nine subjects (82.5%) underwent a CT scan, thus the number of subjects included in analyses based on CT parameters was lower than for those based on lung function. The group assessed for decline of lung function showed no difference in any demographic or clinical feature from those for whom there was insufficient data to assess decline, except that they had smoked slightly more (Table 1 ; p ¼ 0.03).
Genetic association
The allele frequencies of each tag are shown in Table 2 . One SNP (rs5031036) showed poor allelic discrimination (despite optimisation of the genotyping reaction) so was excluded from further analysis, as was rs476762, which was not in Hardy-Weinberg equilibrium. Regression analysis showed association of the G allele of SNP rs678815 (MMP3, p ¼ 0.025, B ¼ 7.766) and the T allele of SNP rs470358 (MMP1, p ¼ 0.025, B ¼ 6.130) with baseline KCO (Figure 1 ). There were no associations with FEV1, decline of FEV1 or emphysema severity in either the upper or lower zone. The linkage disequilibrium plot generated in Haploview is shown in Figure 2 . There were no haplotype associations with FEV1, KCO, FEV1 decline or emphysema severity. [G,A] 7.69 rs476762 [T,A] 16.80 rs678815 [G,C] 45.94 MMP12 rs652438 [G,A] 4.57 rs632009 [T,C] 34.84 rs11225442 [G,A] 14.25 rs17368659 [G,T] 11.60
SNPs are listed using their reference SNP number [major allele, minor allele].
Discussion
The results demonstrate an association of SNP rs678815 (MMP3) and rs470358 (MMP1) with gas transfer (KCO). This is consistent with a protective effect of the T allele of rs470358 such that KCO is 6.13% higher in those carrying at least one T allele in the regression analyses. Similarly the G allele of rs678815 is associated with higher KCO in the regression model, indicating a predisposition to disease for minor allele homozygotes (CC), whose KCO was 7.77% lower on average than other genotypes. The original linkage study in AATD implicating this region of chromosome 11 was powered to detect a protective variant [Stolk, 2007] Therapeutic Advances in Respiratory Disease 3 (1) replication by examining both medical and surgically treated groups, but the SNP was only associated with disease in the surgically treated group. A further study utilising a case-control approach, with the entire NETT cohort as cases and subjects from the normative aging study as controls, did not show any association of the same SNP with emphysema, nor was there association in a family cohort defined by lung function consistent with COPD [Hersh et al. 2005] . No other studies have examined this SNP in relation to lung function decline.
In our study one of the tags covering the promoter region of MMP1 is rs470358. In AATD emphysema zone relates to lung function [Parr et al. 2004] . Thus our results are consistent with the association seen in NETT, though we were unable to confirm this in our analyses based on UZVI, perhaps because of lower numbers in the CT-based studies.
A SNP in MMP12 was also implicated in lung function decline in the Lung Health Study, but only as part of a haplotype with rs1799750 [Joos et al. 2002] . Animal studies have shown deletion of MMP12 to be protective against the development of smoke-related lung injury [Hautamaki et al. 1997] , thus making it a good candidate. Important interactions of AAT and MMP12 have also been observed [Churg et al. 2007 ] providing further rationale for the study of this gene. Again, the association described in usual COPD has not been replicated, and should be viewed with caution. Our results do not show any haplotypes containing both MMP1 and MMP12 tags perhaps because the population studied (although of the same racial group to the Lung Health Study) comes from a different geographical region. Geographical variation has been observed on both the long and short arm of chromosome 11 in a large genome-wide study [WTCCC, 2007] , highlighting the importance of geographical matching in replication studies.
Unlike MMP1 and MMP12, MMP3 has not previously been associated with COPD, nor are there are any specific animal models or in vitro work regarding its protein product in respiratory disease. A recent Japanese study identified a functional polymorphism of a MMP3 promoter SNP as being associated with increased serum MMP3 [Tsukahara et al. 2008] . Elevated pulmonary levels of other MMPs have been observed in emphysema [Betsuyaku et al. 1999; Finlay et al. 1997] and may contribute to disease pathogenesis via increased proteolytic damage to the lung parenchyma. It is conceivable that this is also the case for MMP3, though this now requires further study.
The results presented in this paper have been presented without adjustment for multiple statistical testing. The Bonferroni correction may be overly conservative in genetic association studies, and in a rare disease such as AATD, it may be difficult to recruit sufficient numbers to have the power to achieve genome wide significance (generally considered to be p55 Â 10 À5 [Elston and Ann Spence, 2006] ). Replication of findings in an independent population has, therefore, become an accepted method of validation. Our results represent confirmation of an earlier linkage study, which showed association with lung function in this region in a family cohort with AATD [Stolk, 2007] .
If the genetic association is the result of a primary disease association within an MMP it may support a role for the protein product in pathogenesis, and hence a rationale for targeted treatment. Our results suggest that treatments targeting MMPs might be appropriate in patients with impaired KCO in AATD. A number of treatment strategies aimed at reducing MMP activity might be considered. Synthetic MMP inhibitors or endogenous anti-proteases (TIMPs) are the most direct means of achieving this. The latter could be given to patients as a recombinant protein or by gene therapy [Belvisi and Bottomley, 2003] . However, recombinant proteins are not yet cost effective and gene delivery is unlikely to produce sufficient protein [Belvisi and Bottomley, 2003] . A small study of a synthetic MMP inhibitor in asthma showed some promise in reducing pulmonary inflammation [Bruce and Thomas, 2005] but no trials have been conducted in COPD. A less direct strategy involves the use of tetracyclines which are an established anti-microbial therapy, and also inhibit MMPs [Golub et al. 1998 ]. They have been shown to be both safe and effective in preventing tissue breakdown in nonrespiratory disease [Golub et al. 1998 ]. Our work might logically be followed up by a study of the effects of such drugs in patients with impaired KCO in either AATD or usual COPD [Hill et al. 1999] . Other follow-up work should include fine mapping of the region tagged by associated SNPs, to identify primary disease causing functional variants, and the study of MMP3 and its protein product in AATD or usual COPD.
The main strength of this study is the detailed clinical phenotyping of the patient group. However this also highlights the fact that genetic associations in COPD may not be with all elements of lung function or CT parameters. The results presented herein show an association exclusively with gas transfer, which is a key marker of parenchymal destruction reflective of emphysema. FEV1 is impaired later in the disease process in AATD than KCO and could be affected by airway disease, parenchymal disease, or both. KCO also tends to reflect upper zone emphysema in AATD [Parr et al. 2004] , a phenotype known to be influenced by MMP genotype [DeMeo et al. 2007 ] so the exclusive association with gas transfer seen here might be due to a contribution of MMPs to parenchymal disease alone, or to emphysema zone. The number of patients who had had a CT scan suitable for quantitative analysis was smaller than those that had undergone full lung function, so lower power might be the reason that no association was seen with CT parameters.
The main weakness of this study is the relatively small cohort tested for genetic association, which makes the possibility of a chance association greater. However, since these results support a prior study in AATD [Stolk, 2007] this is perhaps less likely than would be the case if this study was the only one of this genetic region. Nevertheless, as it is the first to tag the region and to examine the full range of COPD phenotypes it may be appropriate to view it as a hypothesis-generating work.
In conclusion, our results further exemplify the role of MMP1 in susceptibility to emphysema, and add to the weight of evidence suggesting similar genetic influences in both AATD and usual COPD. We have also identified a possible role for MMP3 which would now be of value to study in usual COPD. WTCCC (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls, Nature 447: 661-678.
